Home › Funds › Mass General Brigham, Inc › MAZE

Mass General Brigham, Inc position in MAZE

MAZE THERAPEUTICS INC · Health Care

Mass General Brigham, Inc reported holding 249,636 shares of MAZE (MAZE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$6.8M, representing 1.57% of its reported portfolio and ranking #5 among its reported holdings. Mass General Brigham, Inc has disclosed MAZE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)249.64K sh
Reported value held$6.79M
Portfolio Weight1.57%
First reportedQ4 2025
Last changeAdd
Updated2026-11-03

Last updated: 2026-11-03 · Source: SEC EDGAR Form 13F-HR

How Mass General Brigham, Inc's MAZE position evolved

Mass General Brigham, Inc first disclosed a stake in MAZE in Q4 2025 at 239,994 shares (US$9.9M). Across 4 filings, Mass General Brigham, Inc increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 249,636 shares valued at US$6.8M — an increase of 9,642 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q4 2025 239.99K $9.94M New
Q1 2026 239.99K $7.16M Hold
Q2 2026 239.99K $7.16M Hold
Q3 2026 249.64K $6.79M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MAZE and 13F data

MAZE (MAZE THERAPEUTICS INC) is a Health Care company. 74 other funds we track also report a position in MAZE — the largest reported positions include Frazier Life Sciences Management, L.P. (US$150.2M), TRV GP IV, LLC (US$133.5M), ARCH Venture Management, LLC (US$123.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MAZE

All MAZE fund holders →

FAQ

How long has Mass General Brigham, Inc held MAZE?

Mass General Brigham, Inc has disclosed MAZE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Mass General Brigham, Inc's current position in MAZE?

As of Q3 2026, Mass General Brigham, Inc holds 249.64K shares of MAZE (MAZE THERAPEUTICS INC), valued at $6.79M, representing 1.57% of its reported portfolio and ranking #5.

Has Mass General Brigham, Inc been buying or selling MAZE?

In the latest 13F filing (Q3 2026), Mass General Brigham, Inc increased its position in MAZE.

Which other funds hold MAZE?

Other major institutional holders of MAZE include Frazier Life Sciences Management, L.P., TRV GP IV, LLC, ARCH Venture Management, LLC, among 74 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.